REPLIGEN CORP Debt Instrument, Redemption Price, Percentage
REPLIGEN CORP (RGEN) reported Debt Instrument, Redemption Price, Percentage of 25.00% for the 12-month period ending 2023-12-31, per its 10-K/A filed 2024-11-18.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentRedemptionPricePercentage · last filed 2024-11-18
- REPLIGEN CORP debt instrument, redemption price, percentage for fiscal 2023 was 25.00%, a 0.00% change from fiscal 2022.
- REPLIGEN CORP debt instrument, redemption price, percentage for fiscal 2022 was 25.00%.
| Period end | Debt Instrument, Redemption Price, Percentage 12 month |
|---|---|
| 2023-12-31 | 25.00% 10-K/A · filed 2024-11-18 |
| 2022-12-31 | 25.00% 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |